Post-Marketing Surveillance of the Adverse Events Following Immunization with a New Pentavalent Vaccine (DPT-HB+Hib)  by Muzio, V. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e143
19.009
Associations Between Acceptance of Hepatitis B and
Inﬂuenza Vaccination in Health Care Workers
S.S. Lee ∗, D.K.P. Tam
Stanley Ho Centre for Emerging Infectious Diseases, Chinese
University of Hong Kong, Hong Kong, China
Background: In the health care setting, vaccination of
health care workers serves the key purpose of preventing
the occurrence of nosocomial infection. Acceptance of vac-
cination is therefore an important determinant of effective
infection control.Methods: A self-administered question-
naire survey was conducted in 2007 on nurses in Hong Kong.
Participants were asked to indicate their status on inﬂuenza
vaccination in the preceding season, their intention to be
vaccinated in the following year, and hepatitis B vaccination.
Reasons for and against their vaccination were collected.
Results: A total of 781 nurses completed the question-
naires. About half (48.8%) were aged between 36 and 45;
female to male ratio 6:1; and 54.0% had been in nursing
practice for at least 10 years. Above 80% were at fre-
quent or regular contact with patients in the course of
their work. After exclusion of hepatitis B carriers, 90.0%
had received hepatitis B vaccination before or after join-
ing the nursing profession. Overall, 44.3% had received
inﬂuenza vaccination in the preceding season. Of those
eligible for both vaccines, rejection of inﬂuenza vaccina-
tion was associated with long working experience (48.2%
vs 58.3%, OR = 0.67; 95% CI 0.48, 0.93), frequent contact
with patients (56.5% vs 43.9%, OR = 1.67; 95% CI 1.14, 2.38),
perceived ineffectiveness of vaccination (81.5% vs 31.5%,
OR = 7.58; 95% CI 6.46, 14.20) and rejection of hepati-
tis B vaccination (70.7% vs 50.8%, OR = 2.34; 95% CI 1.30,
4.22)
Discussion: The low uptake of inﬂuenza vaccination in
health care workers was associated with a multitude of fac-
tors ranging from perceived ineffectiveness of vaccine, work
nature, as well as attitude towards other vaccines. Infection
control strategies may need to be tailored to the unique
health care setting to achieve better coverage of inﬂuenza
vaccination.
doi:10.1016/j.ijid.2008.05.356
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Background: Combination vaccines are an important
trend in the development of vaccines to reduce the num-
ber of injections and to increase vaccination’s coverage. In
Cuba a new pentavalent vaccine was recently obtained in a
formulation where the DPT-HB component is mixed with the
monovalent Hib vaccine, just immediately before its admin-
istration. This vaccine was introduced into the National
Immunization Program (NIP) since September of 2006.
Objective: Evaluation of the adverse events following
immunization (AEFI) with the pentavalent vaccine admin-
istered under routine use through the NIP.
Methods: It was planned to include 3000-4000 children,
receiving any dose of this vaccine in 42 health areas repre-
senting the whole country. The study was carried out from
September to December 2006. Nurses were trained to fol-
low up all the AEFI occurring in the 72 hours after vaccination
(even causally related or not) and to ﬁll a form containing
all this information, with a scale of classiﬁcation of the most
probably found events. Data bases were designed, ﬁlled by
duplicated, and compared to discard mistakes, before the
analyses.
Results: A total of 4059 children were included, 47.5%
presented some event during the observation period. The
99.6% of events correspond to those asked in the inves-
tigation form. The most frequently adverse events were
fever 44.2%, slight fever 15.7%, irritability 11.6% and pain,
induration and erythema at the injection 14.9%, 5.5% and
5.1%, respectively. Those events represented the 97% out of
the total. Local events represent the 25%. According to the
severity AEFI were classiﬁed as mild (88%), moderate (11.9%)
and severe (0.1%). No death or sequels were reported.
Conclusions: The new pentavalent vaccine is safe and
well tolerated in infants <1 year. The AEFI and commonly
reported events showed no differences respect previous
clinical trials for product registration and vaccines of this
kind
doi:10.1016/j.ijid.2008.05.357
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Background: Priming against strains with pandemic
potential, such as H5N1, with vaccines that induce immuno-
logical memory and cross-reactivity, may form the ﬁrst line
of defence against a pandemic ﬂu. Safe and effective H5N1
vaccines, particularly those that can induce cross-reactive
immunity, are urgently needed for prepandemic vaccination
strategies.
